Every article, report, and earnings note where ABBV appears.
AbbVie is successfully replacing Humira with fast-growing immunology and neuroscience assets, supporting a Buy view despite heavy debt and a rich valuation. Skyrizi, Rinvoq, and neuroscience growth are offsetting legacy erosion and keeping earnings momentum intact.
Marc Lichtenfeld and The Oxford Club are promoting the Ultimate Dividend Package, a free bundle of five dividend-stock reports. We identify the best matches and test the income claims against filings.
Five big pharma stocks are ranked in a countdown, comparing specialty franchises, profitability, valuation, growth and earnings consistency for July 2026.
Talawar Tx is a biotechnology company developing bispecific antibodies for immunology and inflammatory diseases, and it is going public through a merger with JATT II Acquisition Corp. (JATT). The deal is expected to close in the second half of 2026, with the combined company set to trade as TLWR. The bull case is a large $225 million PIPE backing a focused atopic dermatitis program; the bear case is that the lead asset is still preclinical and redemption risk could still shrink the trust cash.
Eli Lilly's next move looks less like a pipeline trade and more like an access trade. Demand was never the problem; broader PBM coverage and expected Medicare access starting July 1 make the revenue conversion story more immediate.
Healthcare’s leadership over tech and semis looks less like a defensive flinch and more like a valuation message from a still-hawkish market. With rates staying restrictive, investors are rewarding nearer-term earnings durability and demanding a higher bar for crowded long-duration growth.
AbbVie Inc. (ABBV) rises after announcing a $10.9 billion all-cash acquisition of Apogee Therapeutics. The deal expands AbbVie’s immunology pipeline and reinforces its post-Humira growth strategy, while strong recent earnings and raised guidance add support to the rally.
Seven dividend growth stocks ranked by investment quality — Amgen, AbbVie, and McDonald's all place, while the top two spots wait at the end of the countdown.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate ABBV ReportCancel anytime